Lataa...
Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia
INTRODUCTION: Diffuse large B-cell lymphoma (dlbcl) accounts for 30%–40% of all non-Hodgkin lymphomas. Approximately 60% of patients are cured with standard treatment. Targeted treatments are being investigated and might improve disease outcomes; however, their effect on cancer drug budgets will be...
Tallennettuna:
| Julkaisussa: | Curr Oncol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Multimed Inc.
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6476431/ https://ncbi.nlm.nih.gov/pubmed/31043812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4565 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|